98%
921
2 minutes
20
The E2F family is conserved from Caenorhabditis elegans to mammals, with some family members having transcription activation functions and others having repressor functions. Whereas C. elegans and Drosophila melanogaster have a single E2F activator protein and repressor protein, mammals have at least three activator and five repressor proteins. Why such genetic complexity evolved in mammals is not known. To begin to evaluate this genetic complexity, we targeted the inactivation of the entire subset of activators, E2f1, E2f2, E2f3a and E2f3b, singly or in combination in mice. We demonstrate that E2f3a is sufficient to support mouse embryonic and postnatal development. Remarkably, expression of E2f3b or E2f1 from the E2f3a locus (E2f3a(3bki) or E2f3a(1ki), respectively) suppressed all the postnatal phenotypes associated with the inactivation of E2f3a. We conclude that there is significant functional redundancy among activators and that the specific requirement for E2f3a during postnatal development is dictated by regulatory sequences governing its selective spatiotemporal expression and not by its intrinsic protein functions. These findings provide a molecular basis for the observed specificity among E2F activators during development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288824 | PMC |
http://dx.doi.org/10.1038/nature07066 | DOI Listing |
Cell Rep
August 2025
Key Laboratory of RNA Innovation, Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China. Electronic address:
In heterogeneous tumors, adjacent CpG sites form methylation haplotype blocks (MHBs), genomic regions where methylation status reflects local epigenetic concordance. While MHBs have been implicated in gene dysregulation, their pan-cancer dynamics and clinical relevance remain unclear. We profiled 110 primary tumors across 11 common solid cancer types, identifying 81,567 MHBs.
View Article and Find Full Text PDFCell Death Differ
August 2025
Molecular Oncology, Faculty of Medicine, University of Leipzig, Leipzig, Germany.
BRCA1 and BRCA2 proteins are crucial for DNA repair through homologous recombination (HR), which predominantly takes place during S and G phases. Their expression is tightly regulated to ensure HR occurs exclusively within these phases. While these proteins are well-established tumor suppressors in hereditary breast and ovarian cancers, their inactivation is rare across all sporadic cancers.
View Article and Find Full Text PDFGenes Dis
November 2025
Department of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, China.
Understanding metastatic osteosarcoma relies on defining the complexity of cell types, their associated molecular profiles, and interactions among cells in the tumor microenvironment. Here, we integrated single-cell and bulk gene expression datasets and revealed that metastatic lesions were highly enriched for osteoblasts (OB). Under the regulation of E2F family members, OB cells harbored enhanced proliferation activity and high differentiation potential.
View Article and Find Full Text PDFBlood Adv
August 2025
MD Anderson Cancer Center, Houston, Texas, United States.
The alarmins, S100A8 (A8) and S100A9 (A9), are low molecular weight proteins belonging to the S100 protein family. A8 and A9 are secreted into the extracellular space and plasma, where they interact with TLR4 (Toll like receptor 4), RAGE (receptor for advanced glycation end products) and CD33. In present studies, we determined the preclinical efficacy of tasquinimod (TQ) against advanced MPN cell lines and patient-derived (PD) CD34+ blastic phase (BP, >5% blasts in PB) MPN cells.
View Article and Find Full Text PDFGlob Med Genet
December 2025
Department of Emergency Abdominal Surgery, Beijing Chaoyang Hospital, Capital Medical University, No.8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing 100020, China.
Background: Cancer stem cells (CSCs) drive colorectal cancer (CRC) progression, metastasis, and therapy resistance, but their heterogeneity limits targeted treatment efficacy. Clarifying the stemness landscape and underlying mechanisms is crucial for developing effective CRC therapies.
Methods: By integrating 10 ×single-cell data from GSE201348 and GSE161277, we constructed a single-cell atlas of nine primary CRC samples.